Table 4 Functional progression (Health Assessment Questionnaire Disability Index (HAQ-DI)) across the European League Against Rheumatism (EULAR) states based on the 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) and DAS28 erythrocyte sedimentation rate(ESR): mean change from baseline
TrialEULAR responseAbatacept groupPlacebo groupCombined group
CRPESRCRPESRCRPESR
(n = 171)(n = 75)(n = 246)
ATTAIN (6 months)Good−1.00 (0.10)−0.82 (0.13)−0.56 (0.28)−0.63 (0.38)−0.95 (0.09)−0.80 (0.12)
Moderate−0.49 (0.06)−0.56 (0.06)−0.21 (0.06)−0.28 (0.06)−0.43 (0.05)−0.50 (0.05)
None−0.18 (0.06)−0.21 (0.05)−0.10 (0.06)−0.07 (0.06)−0.14 (0.04)−0.14 (0.04)
(n = 351)(n = 155)(n = 506)
AIM (6 months)Good−0.89 (0.06)−0.97 (0.07)−1.03 (0.16)−1.20 (0.24)−0.91 (0.05)−0.99 (0.06)
Moderate−0.55 (0.04)−0.57 (0.04)−0.66 (0.06)−0.71 (0.07)−0.59 (0.03)−0.61 (0.03)
None−0.11 (0.05)−0.16 (0.06)−0.18 (0.07)−0.20 (0.07)−0.15 (0.05)−0.18 (0.05)

  • Data are mean (SD).

  • AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders.